Burning Rock Reports Third Quarter 2025 Financial Results

Core Insights - Burning Rock Biotech Limited reported a total revenue of RMB 131.6 million (US$ 18.5 million) for Q3 2025, marking a 2.3% increase from RMB 128.6 million in Q3 2024 [3] - The company achieved a gross profit of RMB 98.8 million (US$ 13.9 million) for the same period, representing a 7.6% increase from RMB 91.8 million in Q3 2024, with a gross margin of 75.1% [5] - The net loss for Q3 2025 was RMB 16.8 million (US$ 2.4 million), a significant improvement compared to a net loss of RMB 35.7 million in Q3 2024 [10] Financial Performance - Total revenues for Q3 2025 were RMB 131.6 million (US$ 18.5 million), up from RMB 128.6 million in Q3 2024 [3] - Cost of revenues decreased to RMB 32.8 million (US$ 4.6 million) in Q3 2025, down 10.9% from RMB 36.8 million in Q3 2024 [4] - Gross profit increased to RMB 98.8 million (US$ 13.9 million) in Q3 2025, with a gross margin of 75.1%, compared to 71.4% in Q3 2024 [5][7] - Non-GAAP gross profit for Q3 2025 was RMB 100.9 million (US$ 14.2 million), a 3.2% increase from RMB 97.8 million in Q3 2024 [8] Revenue Breakdown - Revenue from the in-hospital business was RMB 52.8 million (US$ 7.4 million) in Q3 2025, a 17.1% decrease from RMB 63.8 million in Q3 2024 [6] - Revenue from the central laboratory business was RMB 36.8 million (US$ 5.2 million), down 7.9% from RMB 40.0 million in Q3 2024 [6] - Revenue from pharma research and development services surged to RMB 42.0 million (US$ 5.9 million), a 68.6% increase from RMB 24.9 million in Q3 2024 [6] Operating Expenses - Total operating expenses for Q3 2025 were RMB 115.0 million (US$ 16.2 million), down 11.9% from RMB 130.4 million in Q3 2024 [9] - Research and development expenses decreased to RMB 41.5 million (US$ 5.8 million), a 15.6% decline from RMB 49.2 million in Q3 2024 [13] - Selling and marketing expenses were RMB 41.8 million (US$ 5.9 million), down 13.6% from RMB 48.4 million in Q3 2024 [13] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and restricted cash totaling RMB 467.0 million (US$ 65.6 million) [10]